EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas

Suzanne Agnes Erich, Erik Teske iD

Veterinary and Comparative Oncology · 2024-09 · 22 (3) · 322-339

DOI: 10.1111/vco.12988 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 12.06.2024. Verfasst von Suzanne Agnes Erich und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Dog Diseases, Genetic Variation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges for an animal model with a high incidence to accelerate knowledge about genetics and optimal treatment of HS/DCS. Namely, until now, the therapies targeting genetic variants are still more experimental and sparsely used, while consensus is missing. In addition, the literature about variants and possible mutation‐targeted therapies in humans and dogs consists mainly of case reports scattered throughout the literature. Therefore, an overview is provided of all currently known genetic variants in humans and dogs with HS/DCS and its subtypes, their possible mutation‐targeted therapies, their efficacy, and a contemplation about the future. Several genetic variants have already been discovered in HS/DCS, of which many are shared between canine and human HS/DCS, but unique variants exist as well. Unfortunately, none of these already found variants seem to be specifically causal for HS/DCS, and the puzzle of its landscape of genetic variation is far from complete. The use of mutation‐targeted therapies, including MAPK‐/MEK‐inhibitors and the future use of PTPN11‐, CDK4/6‐ and PD‐1‐inhibitors, seems to be promising for these specific variants, but clearly, clinical trials are needed to determine optimal inhibitors and standardised protocols for all variants. It can be concluded that molecular analysis for variants and subsequent mutation‐targeted therapy are an essential addition to cancer diagnostics and therapy. A joint effort of humans and dogs in research is urgently needed and will undoubtedly increase knowledge and survival of this devastating disease in dogs and humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesGenetic VariationDogsAnimalsHumansOne HealthHistiocytic SarcomaSarcomaDendritic Cells

Stichwörter der Autor:innen

Bernese mountain dogCDKN2AMAPKPTPN11flat‐coated retrieverhistiocytic sarcoma

Autor:innen und Institutionen

  • Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Erik Teske

Zitieren

APA

Erich, S. A., & Teske, E. (2024). One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas. Veterinary and Comparative Oncology, 22(3), 322-339. https://doi.org/10.1111/vco.12988

Vancouver

Erich SA, Teske E. One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas. Veterinary and Comparative Oncology. 2024;22(3):322-339. doi:10.1111/vco.12988

BibTeX
@article{Erich2024,
  author = {Erich, Suzanne Agnes and Teske, Erik},
  title = {One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas},
  journal = {Veterinary and Comparative Oncology},
  year = {2024},
  volume = {22},
  number = {3},
  pages = {322--339},
  doi = {10.1111/vco.12988}
}
Kostenlos starten →